ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1386	National Cancer Institute	Html	en	Delirium (PDQ®)–Health Professional Version	Expert-reviewed information summary about delirium as a complication of cancer or its treatment. Supportive care and pharmacologic approaches to the management of delirium are discussed.	elderly patients 0.428132 palliative medicine 0.41962 Fainsinger RL 0.451294 cancer center 0.422328 parent opioid compound 0.416673 palliative sedation. 0.469946 terminal sedation 0.549416 advanced cancer patients 0.459954 health care personnel 0.42512 QTc prolongation 0.496258 intravenous haloperidol 0.415462 risk factors 0.405793 refractory delirium 0.559163 oral opioid doses 0.440498 patients 0.718812 cancer patients 0.560957 sedation management. 0.490138 Lawlor PG 0.441422 palliative sedation therapy 0.708844 hypoactive delirium 0.522797 Palliat Care 0.456046 Pain Symptom Manage 0.718675 deep palliative sedation 0.612386 et al. 0.454631 study 0.418964	opioid toxicity 0.40801 deep sedation 0.500093 palliative care 0.916963 PUBMED Abstract 0.605152 agitated delirium 0.529672 haloperidol 0.510465 Opioid rotation section 0.412964 Support Care Cancer 0.588217 terminally ill patients 0.594369 delirium 0.992491 palliative sedation 0.977292 palliative care support 0.490339 Delirium reversal 0.553183 advanced cancer 0.474165 acute palliative care 0.478818 palliative care patients 0.570294 Palliat Med 0.428812 ill cancer patients 0.443961 palliative care experience 0.501267 palliative care unit 0.618846 palliative care units 0.586545 versus continuous sedation 0.526162 Injectable haloperidol 0.422082 palliative care programs 0.565085	CLICK HERE
1457	National Cancer Institute	Html	en	Esophageal Cancer Prevention (PDQ®)–Patient Version	Expert-reviewed information summary about factors that may influence the risk of developing esophageal cancer and about research aimed at the prevention of this disease.	cancer treatment 0.286725 cancer prevention trials 0.390926 protective factors 0.401778 following PDQ summaries 0.346585 PDQ cancer information 0.534006 Clinical Trials section 0.298655 esophageal cancer prevention 0.457641 clinical trials 0.60082 kidney damage 0.286456 cancer information summary 0.441092 lower esophagus 0.410035 lower sphincter muscle 0.357661 breast cancer prevention 0.318294 patients 0.3021 cancer patients 0.287439 latest published information 0.293022 cancer risk factor 0.360882 NCI’s PDQ 0.303811 NCI PDQ cancer 0.377375 stomach acid 0.297556 radiofrequency ablation 0.407628 PDQ Screening 0.291859 abnormal cells 0.372908 cancer risk factors 0.361881	Cancer prevention 0.541167 esophageal cancer 0.615396 cancer protective factor 0.339428 esophageal cancer increases 0.350762 Barrett esophagus 0.51844 Cancer Information Service 0.327169 prevention clinical trials 0.346293 Prevention Editorial Board 0.348856 treatment clinical trials 0.298225 National Cancer Institute 0.429589 Nonsteroidal anti-inflammatory drugs 0.365737 PDQ documents 0.293539 new treatment 0.29433 Cancer Care page 0.315656 PDQ database 0.297589 adenocarcinoma 0.336667 PDQ summary 0.318797 cancer clinical trials 0.340291 risk factors 0.504317 cancer information summaries 0.334653 comprehensive cancer information 0.334858 cancer 0.918802 esophagus produce 0.402126 esophagus 0.723728	CLICK HERE
1477	National Cancer Institute	Html	en	Bladder Cancer Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of bladder cancer.	Ta T1 bladder 0.556554 T1 high-grade bladder 0.506904 superficial bladder tumour 0.53364 bacillus calmette-guerin 0.516715 transitional cell carcinoma 0.695076 T1 transitional cell 0.496806 bladder cancer 0.986423 der Meijden AP 0.500317 clinical trials 0.520234 intravesical bacillus Calmette-Guerin 0.513656 primary superficial bladder 0.615094 non-muscle invasive bladder 0.495804 T1 bladder cancer 0.609466 Malignant bladder tumors 0.513021 superficial bladder cancer 0.787159 bladder tumors 0.61916 van der Meijden 0.529014 patients 0.562152 advanced bladder cancer 0.510311 Invasive T1 bladder 0.497584 high-grade T1 bladder 0.499638 newly diagnosed bladder 0.507837 superficial bladder tumors 0.5725 bacillus calmette-guerin therapy 0.514624	metastatic bladder cancer 0.563646 Canadian Bladder Cancer 0.508472 et al. 0.600299 bladder carcinogenesis 0.499935 high-grade bladder cancer 0.517381 bladder cancer. 0.49995 Eur Urol 0.553395 PUBMED Abstract 0.561063 invasive bladder cancer 0.614868 radical cystectomy 0.523916 non-muscle-invasive bladder cancer 0.573969 transurethral resection 0.509808 bladder cancer coincides 0.50967 advanced bladder carcinoma 0.508345 Abstract 0.681067 Herr HW 0.527009 Clin Oncol 0.566437 bladder carcinoma 0.546923 Urol 0.572506 urothelial carcinoma 0.574639 invasive bladder carcinoma 0.507022 nonmuscle-invasive bladder cancer 0.533359 Low-grade bladder cancers 0.509091 bladder cancer health 0.52478	CLICK HERE
1651	National Cancer Institute	Html	en	Milk Thistle (PDQ®)–Patient Version	Expert-reviewed information summary about the use of milk thistle as a treatment for people with cancer.	cancer treatment 0.701214 advanced liver cancer 0.66555 PDQ cancer information 0.729457 Cancer Complementary 0.666923 clinical trials 0.798052 U.S. Food 0.649163 cancer information summary 0.699946 alternative cancer therapies 0.663524 clinical trial 0.731299 CAM cancer research 0.657056 patients 0.673877 cancer patients 0.654835 randomized clinical trial 0.683387 Marian thistle 0.690666 NCI PDQ cancer 0.677418 cancer information database 0.662437 radiation therapy 0.660512 Therapies Editorial Board 0.664492 cancer information 0.734643 treatment 0.70795 cancer prevention 0.650452 Complementary Therapies Editorial 0.677699 United States 0.665688 Drug Administration 0.682045	Cancer Information Specialist 0.658528 cancer cells 0.669779 milk thistle supplements 0.741182 cancer cell lines 0.655527 anticancer medications 0.651405 Cancer Information Service 0.697895 CAM therapies 0.649867 treatment clinical trials 0.654645 National Cancer Institute 0.770559 alternative medicine 0.692591 conventional treatment 0.650077 St. Mary thistle 0.707197 Federal Trade Commission 0.651646 silymarin 0.670265 Cancer Care page 0.650369 breast cancer 0.668147 PDQ summary 0.650118 cancer clinical trials 0.667946 alternative therapies 0.674881 acute lymphoblastic leukemia 0.665296 neck cancer 0.65549 cancer information summaries 0.662842 colorectal cancer cells 0.652543 cancer 0.828322	CLICK HERE
1903	National Cancer Institute	Html	es	Tratamiento del linfoma no Hodgkin infantil (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento del linfoma no Hodgkin infantil.	siguientes procedimientos 0.533869 posibles efectos tardíos 0.429839 células madre 0.925937 posibles factores 0.42224 adultos jóvenes 0.471015 estadio iv 0.456127 Burkitt recién 0.429453 sistema linfático.Para 0.433317 faja ajustadora 0.424807 gen alk 0.453637 leucemia linfoblástica aguda 0.499911 estadio ii 0.457571 siguientes especialistas 0.421884 siguientes tipos 0.435023 rayos x 0.42189 después.ampliar ecografía 0.422758 enlace drugs approved 0.552427 niño ayuda 0.422955 Sudores nocturnos 0.425131 ondas sonoras 0.421599 células t 0.997508 efectos tardíos 0.61792 PDQ Efectos tardíos 0.432774 líquido cefalorraquídeo 0.752047	sección linfoma 0.486518 Linfoma folicular tipo 0.701733 linfocitos b 0.461134 La terapia 0.636115 encontrarlo.ampliar exploración 0.423664 determinados cambios 0.538253 PDQ Tratamiento 0.508964 líquido incoloro 0.436562 explorador tep 0.424899 siguientes factores 0.424861 sistema nervioso central 0.543338 proteína llamada cinasa 0.449366 mayores probabilidades 0.423685 Non-Hodgkin Lymphoma 0.486305 estadio i 0.458742 tipo paniculitis 0.446711 Estados Unidos 0.425103 estadio iii 0.456847 tejido linfoide 0.449965 ósea fabrica glóbulos 0.477114 almacena glóbulos 0.436048 células b 0.553761 Hodgkin infantil recidivante 0.525837	CLICK HERE
1922	National Cancer Institute	Html	es	Tratamiento del cáncer de próstata (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento del cáncer de próstata.	paciente presente síntomas 0.437409 siguientes procedimientos 0.452293 dé tratamiento 0.439746 estadio iv 0.493208 hiperplasia prostática benigna 0.97293 ecografía transrectal 0.704162 pequeña cantidad 0.628387 peores efectos 0.412864 estadio ii 0.558135 siguientes tipos 0.419876 tumor dosis 0.421814 rayos x 0.418531 sistema urinario masculino 0.436824 ondas sonoras 0.422219 principal fuente 0.412408 características sexuales masculinas 0.423477 enlace medicamentos 0.465713 National Cancer Institute 0.412027 sustancia radiactiva llamada 0.426571 biopsia.ampliar ecografía 0.431707 Instituto Nacional 0.421293 estadios iia 0.418459	hormonas masculinas 0.458793 PDQ Tratamiento 0.424516 hormonas sexuales masculinas 0.442195 estadio iia 0.431816 siguientes problemas 0.426176 presente sección 0.409743 tejidos cercanos.A veces 0.421604 Physician Data Query 0.443132 posibles problemas 0.411863 Estados Unidos 0.4216 estadio iii 0.498677 linfadenectomía pélvica 0.487486 prostatectomía radical.ampliar resección 0.439705 aparato reproductor masculino 0.440962 siguientes sustancias 0.416831 hipertrofia prostática benigna 0.438255 alta intensidad 0.548873 prostatectomía retropúbica 0.464416 Ganas repentinas 0.423669 próstata solas 0.515159 siguientes pruebas 0.46951 siguientes estadios 0.460134	CLICK HERE
1987	National Cancer Institute	Html	es	Tratamiento de los tumores embrionarios del sistema nervioso central infantil (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento del meduloblastoma infantil, los tumores embrionarios distintos del meduloblastoma y los tumores pineales infantiles.	sumario versa 0.501558 siguientes procedimientos 0.502311 células madre 0.524991 efectos secundarios meses 0.503043 siguientes aspectos 0.500523 años edad 0.500492 tratamiento mejora 0.501438 dosis pequeñas administras 0.501281 PDQ Descripción 0.501938 sección información 0.50094 efectos tardíos 0.505196 carcinoma nevoide 0.50085 PDQ Tumores 0.506016 PDQ Efectos tardíos 0.501814 líquido cefalorraquídeo 0.521206 punción espinal.Ampliar 0.500903 National Cancer Institute 0.5005 tumores benignos 0.508351 siguientes riesgos 0.500413 médula ósea.ampliar aspiración 0.502403 Instituto Nacional 0.501732	PDQ Tratamiento 0.505028 presente sumario 0.501062 determinados cambios 0.501002 riesgo promedio 0.513411 nuevos tipos 0.500625 riesgo alto.Riesgo promedio 0.501723 sistema nervioso central 0.814928 Physician Data Query 0.50178 brain tumor 0.501055 prueba irm 0.500762 Aboutâ„¢ Brain Tumors 0.500627 siguientes enfermedades 0.501038 cuánto tumor 0.503396 tumores embrionarios 0.994005 imágenes seguirán 0.500378 Cuánto tiempo 0.500383 siguientes enlaces 0.500476 SNC infantil recidivantes 0.502864 Brain Tumor Consortium 0.501941 infantil recidivantes 0.502523 siguientes pruebas 0.501153	CLICK HERE
16652	National Cancer Institute	Html	en	Track 2: Oncology Product Research and Review for B.C. Oncologists	NCI and FDA collaborate to train physicians in aspects of drug, biologic, or device development and standards for assessing medical product safety. Learn more about this cancer training program.	regulatory research 0.59502 pre-screened pool 0.579358 related issues 0.586202 reviewer training 0.576269 FDA scientific review 0.753981 later potential exposure 0.734497 regulatory meetings 0.582894 permanent residency 0.578922 Medical Center Dr 0.681374 fellows 0.986099 application guidelines 0.556272 clinical trials 0.592135 translational research 0.577443 various courses 0.556327 grand rounds 0.56318 various regulatory activities 0.729982 Regulatory Review Fellowships 0.720449 Cancer Training 0.567352 branch chief 0.561743 clinical divisions 0.572535 FDA Centers 0.764003 Review list 0.568699 training program 0.574879 application materials 0.560557 relevant federal statutes 0.739941	formal training 0.600328 U.S. citizenship 0.583794 earliest start date 0.680448 particular product 0.577316 office meetings 0.559685 senior member 0.553306 regulatory presentations 0.582975 guidance document development 0.691126 designee 0.446918 basic bench science 0.743323 principal investigators 0.569533 medical product safety 0.755593 Office Phone 0.552001 NCI-FDA Research 0.556736 one-year program 0.583619 supplemental training 0.588935 division director 0.57667 efficacy 0.476236 limited human exposure 0.741021 FDA medical review 0.830025 device development 0.579671 broader patient population 0.734715 clinical reviews 0.569332 pharmacology/toxicology 0.443629	CLICK HERE
16833	National Cancer Institute	Html	en	News and Events	The latest news from the Office of Cancer Nanotechnology Research and the Alliance, as well as upcoming and past events attended by the Office of Cancer Nanotechnology Research staff, and relevant upcoming scientific meetings.	National Cancer Institute 0.924974		CLICK HERE
17170	National Cancer Institute	Html	es	PC-SPES (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos sobre el uso de PC-SPES como tratamiento del cáncer de próstata. Nota: La información contenida en este sumario ya no se actualiza y se ofrece solo con fines de consulta.	Hsieh TC 0.512609 cell lines 0.580614 DiPaola RS 0.518041 herbal compound 0.512202 cell cycle arrest 0.510653 Panax ginseng 0.534566 androgen-dependent lncap cells 0.510949 herbal formulation 0.520455 próstata lncap 0.510141 herbal combination 0.538545 Cancer Res 0.532897 Cancer Prev 0.510115 PC-SPES which 0.510153 PSA Rising 0.510712 Estados Unidos 0.514599 Natl Cancer Inst 0.529649 Pirani JF 0.524938 LNCaP cells 0.518113 pc-spes contenía des 0.513216 patients with 0.561272 In vitro mechanism 0.515105 Taille A 0.52428 Scutellaria baicalensis 0.522111 prostate carcinoma 0.52183 panax ginseng c.a 0.528442	George DJ 0.512309 herbal compound pc-spes 0.515596 Oh WK 0.520298 Nutr Cancer 0.510533 Hayek OR 0.509996 Glycyrrhiza uralensis 0.513578 using pc-spes 0.518341 células lncap 0.515795 Serenoa repens 0.547922 Ganoderma lucidum 0.527517 PC-SPES demostró actividad 0.512446 cell cycle 0.533145 PC SPES 0.530969 herbal composition pc-spes 0.529409 Buttyan R 0.516728 vitro toxicity mediated 0.512005 recent clinical trials 0.523629 Prostate Cancer Survivor 0.513926 herbal therapy pc-spes 0.566579 herbal supplement pc-spes 0.555382 Chinese herbal 0.520945 prostate cancer 0.978435 datos probatorios 0.516673 in vitro 0.808088	CLICK HERE